Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163176
Status:
COMPLETED
Last Update Posted:
2011-12-16
First Post:
2005-09-09
Brief Title:
Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors
Sponsor:
Radboud University Medical Center
Organization:
Radboud University Medical Center
Study Overview
Official Title:
Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tumor cell proliferation and repopulation contribute to resistance to radiotherapy in head and neck cancer Up to now this characteristic is mostly assessed using biopsies acquired during inspection under general anaesthesia before treatment
18F-FLT-PET positron emission tomography is a non-invasive imaging method showing areas of active proliferation The aim of this study is to assess the value of the functional information gained by 18F-FLT-PET for radiotherapy planning and early tumor response assessment
Prior to radiotherapy a planning CT-scan and a 18F-FLT-PET scan are acquired After approximately two weeks of radiotherapy a further PET scan is obtained
18F-FLT-PET positron emission tomography is a non-invasive imaging method showing areas of active proliferation The aim of this study is to assess the value of the functional information gained by 18F-FLT-PET for radiotherapy planning and early tumor response assessment
Prior to radiotherapy a planning CT-scan and a 18F-FLT-PET scan are acquired After approximately two weeks of radiotherapy a further PET scan is obtained
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None